Drug Approval | December 27, 2025
EU nod to Wayrilz as breakthrough treatment for hard-to-treat ITP
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Full approval will depend on verification of clinical benefit in a confirmatory trial
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhoea
The formulation is backed by over 80 clinical trials and 200 scientific publications
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Subscribe To Our Newsletter & Stay Updated
